Table 2.
CARTr characteristics by indication
| Peripheral BCR | Hematogones | CD19+ MRD or relapse | Nonresponse to CARTi | |
|---|---|---|---|---|
| n = 40 | n = 23 | n = 10 | n = 8 | |
| Peripheral CD19+ cells or CD19+ hematogones prereinfusion, % | 7.3 (5.5-19.7) Absolute CD19/μL, 86 (39-166) |
2.0 (0.1-6.5) | — | — |
| BM blasts prereinfusion, % | — | — | 0.16 (0.0-70.0)∗ | 90.0 (5.2-96.5)† |
| Extramedullary disease prereinfusion, n (site) | — | — | 4 (CNS, orbit, breast, mediastinum) | 0 |
| Months from initial infusion to reinfusion | 3.6 (3.2-5.2) | 3.8 (3.4-4.6) | 9.5 (4.1-22.8) | 1.2 (0.9-1.4) |
| CARTr dose, CAR T cells × 106/kg | 4.9 (2.3-6.5) | 4.1 (3.8-6.3) | 5.4 (2.4-6.7) | 5.6 (2.5-9.0) |
| Lymphodepletion prereinfusion | ||||
| Standard Flu/Cy | 24 (60.0) | 4 (17.4) | 6 (60.0) | 3 (37.5) |
| Lower dose Flu/Cy | 4 (10.0) | 1 (4.3) | 1 (10.0) | 0 (0.0) |
| Cy/Prednisone | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (12.5) |
| No lymphodepletion | 12 (30.0) | 18 (78.3) | 3 (30.0) | 4 (50.0) |
| Received pembrolizumab | 4 (10.0) | 1 (4.3) | 3 (30.0) | 3 (37.5) |
| CR to first reinfusion | 15 (37.5) | 18 (78.3) | 5 (50.0) | 0 (0.0) |
| With LD chemo | 14/28 (50.0) | 3/5 (60.0) | 4/7 (57.1) | 0/4 (0.0) |
| Without LD chemo | 1/12 (8.3) | 15/18 (83.3) | 1/3 (33.3) | 0/3 (0.0) |
| Received second reinfusion, n (%) | 13 (32.5) | 11 (47.8) | 2 (20.0) | 0 (0.0) |
Data are displayed as median (IQR) unless otherwise indicated.
BM, bone marrow; CNS, central nervous system; Cy, cyclophosphamide; Flu, fludarabine; LD, lymphodepleting.
Data are displayed as n (%) unless otherwise indicated.
BM, bone marrow.
∗
n = 9 (not available on 1 patient).
†
n = 7 (not available on 1 patient).